Xtl Biopharmaceuticals XTLB
NASDAQ XTLB
$1.94 -0.02 (-1.02%)
As of: Oct 20, 2026 · 3:58 PM EDT

Xtl Biopharmaceuticals (XTLB) Current Deferred Revenue (2012)

Updated

Analysis

Xtl Biopharmaceuticals (XTLB) Current Deferred Revenue (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Xtl Biopharmaceuticals 18.55 Mn 15.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 555,152.86
Sep 30, 2012 817,680.99
API Access

Xtl Biopharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=XTLB&period=max&api_key=YOUR_API_KEY